Hinova Pharmaceuticals Inc. (SHA:688302)
China flag China · Delayed Price · Currency is CNY
40.76
-0.20 (-0.49%)
At close: Apr 29, 2026

Hinova Pharmaceuticals Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Market Capitalization
4,0364,8693,0415,1563,992-
Upgrade
Market Cap Growth
24.99%60.11%-41.02%29.14%--
Upgrade
Enterprise Value
3,3134,0582,1413,9912,299-
Upgrade
Last Close Price
40.7649.1730.7152.0740.32-
Upgrade
PS Ratio
86.80237.848289.18-2418.38-
Upgrade
PB Ratio
3.904.582.553.772.52-
Upgrade
P/TBV Ratio
4.024.722.623.862.57-
Upgrade
EV/Sales Ratio
71.26198.255837.54-1392.58-
Upgrade
Debt / Equity Ratio
0.100.100.010.010.020.01
Upgrade
Net Debt / Equity Ratio
-0.70-0.60-0.70-0.80-0.97-1.14
Upgrade
Net Debt / EBITDA Ratio
4.954.203.703.264.432.62
Upgrade
Net Debt / FCF Ratio
4.843.353.023.083.993.62
Upgrade
Asset Turnover
0.040.020-0.00-
Upgrade
Inventory Turnover
0.120.2066.31-134.51-
Upgrade
Quick Ratio
6.655.955.7510.3411.354.71
Upgrade
Current Ratio
7.047.206.0310.7411.654.99
Upgrade
Return on Equity (ROE)
-12.29%-12.17%-15.59%-19.93%-25.40%-34.50%
Upgrade
Return on Assets (ROA)
-7.26%-7.36%-9.98%-13.04%-16.00%-19.89%
Upgrade
Return on Capital Employed (ROCE)
-13.00%-13.30%-18.80%-24.30%-21.80%-43.60%
Upgrade
Earnings Yield
-3.35%-2.82%-6.56%-5.71%-7.55%-
Upgrade
FCF Yield
-3.70%-3.94%-9.10%-6.88%-9.62%-
Upgrade
Buyback Yield / Dilution
1.18%0.51%-0.21%-9.06%-22.21%-5.74%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.